New radioactive tracer aims to illuminate hidden prostate cancer

NCT ID NCT07236112

Ongoing Diagnosis Sponsor: C Ray Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests TRDC002, a radioactive tracer that attaches to PSMA proteins on prostate cancer cells, to improve PET/CT imaging in patients whose cancer has returned or spread. Six adults with PSMA-positive recurrent or metastatic prostate cancer will receive a single dose of TRDC002 and undergo PET/CT scans. The goal is to find the best dose and timing for clear images, while also checking safety and how the tracer moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TRDC002 (a radioactive tracer using copper-64 to bind to PSMA proteins on prostate cancer cells)
What this could lead to: If successful, this could provide a more accurate imaging method to detect where prostate cancer has spread, helping doctors choose better treatments.
What could go wrong: This is a very early Phase 1 trial with only 6 participants, so results may not apply to all patients. The tracer may not clearly show all cancer spots, and there are unknown safety risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Union Hospital, Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, 430022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.